Physician profile
Danielle Malvini
NPI 1598177164
$1,986.08
in general payments reported to CMS, 2019-2025
22 companies · $739 in 2025
The $739 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.54 · 2020: $131 · 2021: $364 · 2022: $260 · 2023: $49.40 · 2024: $431 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,187 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.17 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $493.23 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $280.25 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Biohaven Pharmaceuticals, INC. | $174.95 | 2021 | |
| Corcept Therapeutics | $174.34 | 2025 | Korlym |
| Lilly USA, LLC | $125.78 | 2020-2025 | Mounjaro |
| Biohaven Pharmaceutical Holding Company Ltd. | $85.80 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.78 | 2021-2024 | Trintellix |
| Abbvie INC. | $84.49 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $65.34 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.47 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $52.89 | 2024-2025 | |
| Glaxosmithkline, LLC. | $49.25 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lupin INC. | $38.18 | 2019-2020 | |
| Genentech USA, INC. | $35.32 | 2021 | |
| Sanofi-Aventis U.S. LLC | $31.91 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $29.38 | 2025 | |
| Arbor Pharmaceuticals, INC. | $24.14 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $22.66 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.28 | 2024 | Voquezna |
| Exact Sciences Corporation | $19.07 | 2023 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $16.14 | 2023 | Third Wave |
| Amarin Pharma, INC. | $15.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Malvini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.